Data coverage, completeness and provenance for INVION LIMITED in the Stock Market API — Health Care · Drug Manufacturers - Specialty & Generic.
Source date: 2026-10-30T03:15:13. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.0340 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.0370 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.0370 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.0370 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.0370 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/IVX/prices · Price parameters and adjustment semantics
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Website: https://www.inviongroup.com · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/IVX/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 28 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 23 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 27 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 26 | yfinance | ||||
| FY2022 (AUD) | 2022-06-30 | 27 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/IVX
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/IVX/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/IVX/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/IVX/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/IVX/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/IVX
Free tier — instant API key. Built for AI agents.